Sandwich Assay Design for Small Molecule Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for fast and accurate diagnostic methods to measure levels of immunosuppressant drugs like sirolimus in patients, as their narrow effective dose range and varying distribution and metabolism between patients require precise monitoring to avoid serious side effects and tissue rejection.
Innovation Solution
The development of monoclonal antibodies that can specifically bind to separate portions of sirolimus, enabling a sandwich assay to accurately determine the presence and amount of the drug in samples, minimizing cross-reactivity with metabolites and other sample constituents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional single-antibody assays are used to detect immunosuppressant drugs, then the assay design is simple, but the measurement precision is poor due to cross-reactivity with metabolites and sample constituents
Solution Approach 1:
The patent applies segmentation by using two distinct monoclonal antibodies that bind to different epitopes on the immunosuppressant drug molecule. The first antibody binds to a first epitope while the second antibody binds to a second epitope, allowing the assay to specifically detect the parent drug molecule without cross-reacting with metabolites. This segmented approach divides the binding function into separate components, each targeting specific regions of the drug molecule, thereby improving measurement precision while maintaining reasonable assay complexity through the use of standardized sandwich assay format.
2Reliability
If monoclonal antibodies binding to separate portions of the drug are used, then cross-reactivity with metabolites is minimized, but the difficulty of detecting and measuring increases due to the need for specific epitope targeting
Solution Approach 1:
The patent applies local quality by designing monoclonal antibodies with specific binding characteristics tailored to different epitopes on the drug molecule. The first monoclonal antibody is designed to bind to a specific first epitope while the second monoclonal antibody is designed to bind to a specific second epitope. This localized binding approach ensures that each antibody targets a specific region of the drug molecule, minimizing cross-reactivity with metabolites and other sample constituents. The local quality of each antibody's binding site is optimized to provide high specificity while the overall assay remains measurable through standard detection methods.
3Measurement precision
If fast and accurate diagnostic methods are developed, then dosing precision is improved, but the ease of operation decreases due to the complexity of monoclonal antibody preparation and assay setup
Solution Approach 1:
The patent applies universality by developing a sandwich assay system that can be applied to detect various immunosuppressant drugs (such as sirolimus, everolimus, and other rapamycin derivatives) using the same fundamental principle of dual monoclonal antibody binding. The assay methodology is designed to be universally applicable to different drugs in the same class, allowing for standardized operation procedures. The multi-functional capability of the assay system enables precise dosage monitoring across different immunosuppressant medications while maintaining consistent operational protocols, thereby improving measurement precision without proportionally increasing operational complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for sensitive and accurate monitoring of sirolimus levels, enhancing the precision of dosing regimes and reducing the risk of adverse reactions by selectively detecting the parent molecule while accounting for its metabolites and sample impurities.
Implementation Method 1
The development of monoclonal antibodies that can specifically bind to separate portions of sirolimus, enabling a sandwich assay to accurately determine the presence and amount of the drug in samples
Data Source
AI summary
Methods are disclosed of designing antibodies for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,000. The method comprises preparing a first antibody that binds to the small molecule, and preparing a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a predetermined portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.